PA
BMY.RT

Pinnacle Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Pinnacle Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,029
Closed -$31K – 766
2020
Q4 		$31K Sell
45,029
-1,875
-4% -$3.99K ﹤0.01% 701
2020
Q3 		$106K Buy
46,904
+13,075
+39% +$37.3K ﹤0.01% 659
2020
Q2 		$121K Sell
33,829
-480
-1% -$1.73K ﹤0.01% 651
2020
Q1 		$130K Sell
34,309
-1,335
-4% -$4.4K ﹤0.01% 625
2019
Q4 		$107K Buy
+35,644
New +$92.7K ﹤0.01% 697

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Pinnacle Associates's BMY.RT Position: Q1 2021 in Review

Pinnacle Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 45,029 shares — an estimated $31K sold.

Pinnacle Associates first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $130K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Pinnacle Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Pinnacle Associates sold 45,029 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $31K.
  • Pinnacle Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Pinnacle Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $130K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Pinnacle Associates's 13F filing for Q1 2021, filed 12 May 2021.